INCY
Incyte Corporation · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 433.49K | $48.73M | n/a | n/a |
| Q2 2026 | 154 | 0 | 131.73M | $14.93B | +4 | −5 |
| Q1 2026 | 158 | +1 | 132.61M | $12.47B | +5 | −5 |
| Q4 2025 | 156 | -1 | 139.13M | $13.74B | +1 | −1 |
| Q3 2025 | 24 | 0 | 89.63M | $7.60B | n/a | −1 |
| Q2 2025 | 22 | +1 | 88.20M | $6.01B | +1 | n/a |
| Q1 2025 | 18 | -1 | 44.33M | $2.68B | n/a | −1 |
| Q4 2024 | 19 | +1 | 43.85M | $3.03B | +1 | n/a |
| Q3 2024 | 17 | 0 | 35.50M | $2.35B | +1 | −1 |
| Q2 2024 | 17 | n/a | 33.47M | $2.03B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Dodge & Cox ✦ | 15.28M | n/a | $926.23M | 0.6% | n/c | 1 | SEC ↗ |
| 2 | Renaissance Technologies ✦ | 5.22M | n/a | $316.34M | 0.5% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 4.05M | n/a | $244.63M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | AQR Capital Management ✦ | 2.66M | n/a | $159.91M | 0.2% | n/c | 1 | SEC ↗ ×5 |
| 5 | Norges Bank ✦ (passive) | 2.12M | n/a | $128.77M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | D. E. Shaw & Co. ✦ | 1.23M | n/a | $74.76M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 7 | Citadel Advisors ✦ | 821.67K | n/a | $49.81M | 0.1% | n/c | 1 | SEC ↗ ×2 |
| 8 | Millennium Management ✦ | 420.30K | n/a | $25.48M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | ARK Investment Management ✦ | 398.66K | n/a | $24.17M | 0.2% | n/c | 1 | SEC ↗ |
| 10 | Capital World Investors ✦ | 396.00K | n/a | $24.01M | 0.0% | n/c | 1 | SEC ↗ |
| 11 | T. Rowe Price ✦ | 225.11K | n/a | $13.65M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | Two Sigma Investments ✦ | 218.08K | n/a | $13.22M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Wellington Management ✦ | 174.83K | n/a | $10.60M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 14 | Bridgewater Associates ✦ | 127.13K | n/a | $7.71M | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Gotham Asset Management ✦ | 80.14K | n/a | $4.86M | 0.1% | n/c | 1 | SEC ↗ |
| 16 | Marshall Wace ✦ | 33.54K | n/a | $2.03M | 0.0% | n/c | 1 | SEC ↗ |
| 17 | Fisher Asset Management ✦ | 9.26K | n/a | $561,256 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 805 holders, 201.47M shares, $18.13B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 2.64K sh · $297,780
Officer · 13.98K sh · $1.69M
Officer · 9.23K sh · $1.11M
Officer · 10.80K sh · $1.36M
Officer · 10.80K sh · $1.30M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology